Does Olive Oil Actually Improve Blood Sugar — or Is the Diabetes Claim Overstated?

Study Overview

The study, “The Effect of Different Types of Olive Oil on Glucose Control and Insulin Sensitivity: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of 51 Randomized Controlled Trials,” was published in Nutrition Reviews in 2026 by Alireza Takhttavous and colleagues. It is a systematic review and meta-analysis, not a single intervention trial, and it was prospectively registered on PROSPERO as CRD42023459523.

The authors searched PubMed, Scopus, and Web of Science for randomized controlled trials testing olive oil interventions and reporting glycemic outcomes. Their search began with 2,705 articles, 115 were assessed in full text, and 51 trials with 4,334 adult participants were included in the quantitative meta-analysis. Outcomes were pooled as weighted mean differences with 95% confidence intervals, using fixed- or random-effects models depending on heterogeneity.

The paper is especially useful because it examined several endpoints separately: blood glucose, fasting insulin, hemoglobin A1c, and HOMA-IR, a common surrogate marker of insulin resistance. It also ran dose-response analyses, which is where the story gets more interesting than the headline “olive oil helps diabetes.”

Key Findings: The Actual Numbers

The pooled headline is deliberately underwhelming. Across all included trials, olive oil did not significantly change glucose, insulin, HbA1c, or HOMA-IR. That matters. It means we should not describe olive oil as a direct, reliable glucose-lowering treatment based on the randomized evidence as a whole.

But the dose-response analysis complicates the story. The authors found a significant nonlinear relationship between olive-oil dose and HOMA-IR (P = 0.024), and between intervention duration and HOMA-IR (P = 0.025), insulin (P = 0.002), and HbA1c (P = 0.048). Their conclusion was that a daily dose of 25-50 g of olive oil significantly improves HOMA-IR, even though the all-trial average effect was not significant.

Mechanism: Why Insulin Resistance May Move Before Glucose

The biology is plausible, but it is not magic. Olive oil is rich in oleic acid, a monounsaturated fatty acid that can replace refined carbohydrate, butter, or seed-oil-heavy processed foods in the diet. That substitution can improve postprandial lipid handling, membrane composition, and inflammatory tone — all relevant to insulin signaling.

Extra virgin olive oil adds a phenolic fraction that refined olive oil largely lacks: hydroxytyrosol, tyrosol, oleuropein derivatives, oleocanthal, oleacein, and related secoiridoids. These compounds interact with oxidative-stress and inflammatory pathways, including NRF2 antioxidant signaling, NF-κB inflammatory signaling, endothelial nitric-oxide biology, and LDL oxidation. In insulin-resistant states, oxidative stress and low-grade inflammation can interfere with insulin-receptor signaling and glucose transport.

That helps explain why HOMA-IR may be the more sensitive endpoint. Fasting glucose and HbA1c are relatively blunt: they often stay normal until metabolic dysfunction is more advanced, or they require larger/longer interventions to move. Insulin resistance can improve before fasting glucose visibly changes. So a HOMA-IR signal at 25-50 g/day is biologically coherent, even if it is not yet a clinical-outcomes result.

Context: How This Compares With Previous Olive-Oil Research

This meta-analysis lands in the middle of the evidence map. Individual trials often look more exciting: high-phenolic EVOO studies have reported improvements in oxidized LDL, antioxidant capacity, endothelial function, HOMA-IR, and inflammatory markers. Mediterranean-diet trials also consistently suggest better cardiometabolic outcomes when olive oil replaces less healthy fats.

The new paper acts as a useful corrective. When 51 RCTs are pooled, the average effect on classic glycemic markers is small and statistically non-significant. That does not contradict the better single-study signals; it tells us they are context-dependent. Population, baseline metabolic risk, comparator fat, olive-oil type, dose, phenolic content, and duration probably decide whether the signal appears.

Limitations

• • High heterogeneity: insulin heterogeneity was very high (I² = 91.49%) and HOMA-IR heterogeneity was also substantial (I² = 73.13%).
• • Mixed interventions: “olive oil” can mean refined oil, virgin oil, extra virgin oil, high-phenolic EVOO, or diet patterns where olive oil is one component.
• • Surrogate endpoints: HOMA-IR is useful, but it is not the same as reduced diabetes incidence, fewer complications, or lower medication burden.
• • Comparator problem: the effect of olive oil depends heavily on what it replaces. Replacing butter is different from replacing nuts, avocado, or another unsaturated fat.
• • Abstract-level reporting: the accessible report gives the key pooled estimates and dose-response significance, but the precise subgroup effect sizes require full-table access.

Our Take

This is a strong paper because it is large for the question, randomized-trial based, and appropriately skeptical. It prevents overclaiming. The all-trial averages say olive oil does not reliably lower fasting glucose, insulin, HbA1c, or HOMA-IR when every intervention is treated together.

But it also gives a smarter practical message: dose and context matter. The 25-50 g/day HOMA-IR signal is not game-changing on its own, but it is consistent with the broader high-quality EVOO literature. My read: olive oil is not a diabetes treatment, but fresh extra virgin olive oil used daily as the main dietary fat is a rational metabolic-health move — especially when it displaces worse fats and comes packaged inside a Mediterranean-style diet.

Reference

Takhttavous A, et al. The Effect of Different Types of Olive Oil on Glucose Control and Insulin Sensitivity: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of 51 Randomized Controlled Trials. Nutrition Reviews. 2026;84(2):345-365. doi: 10.1093/nutrit/nuaf099. PMID: 40971936.